# Anuncia Medical - Strategic Goals & Objectives

## Company Overview

**Anuncia Medical** is a neurotherapeutic device company developing noninvasive solutions for cerebrospinal fluid (CSF) management and neurocritical care. Based in Scottsdale, Arizona, the company addresses the critical problem of shunt occlusions—a leading cause of repeat brain surgeries.

### Key Products
- **ReFlow™ Mini Flusher** (Commercial): FDA-cleared, implanted device allowing patients to manually clear shunt blockages at home
- **ReFlow™ EVD Flusher** (Launching 2026): External ventricular drain flusher for ICU use - FDA Breakthrough Device Designation
- **Monitoring System** (Pipeline): Intracranial pressure and brain compliance monitoring via Arizona State University license

### Market Position
- Commercial in 35 US hospitals
- Targeting hydrocephalus patients (100,000+ shunt procedures annually in US)
- 40% shunt failure rate in first year, predominantly from occlusions
- Value proposition: Reduce revision surgeries by >50%, empower patients, covered by insurance

---

## Strategic Objectives 2024-2025

### 1. Marketing & Brand Excellence

**Primary Goal:** Establish Anuncia Medical as the trusted leader in shunt management innovation

#### Immediate Actions (Q4 2024)
- **Brand Refresh**: Modernize visual identity while preserving snow leopard heritage and orange/gray palette
- **Website Overhaul**: Complete rebuild from WordPress to modern platform with AI-enabled SEO
- **PEDS Conference Video** (December 5, 2024): Professional booth video showcasing ReFlow™ Mini Flusher
- **Social Media Activation**: Launch consistent posting schedule across LinkedIn, Twitter, and platforms

#### Ongoing Initiatives
- **Video Content Library**: Create templates for sales team, KOL interviews, patient testimonials, product explainers
- **Brand Guidelines**: Comprehensive guide ensuring consistency across all materials, presentations, and communications
- **Content Strategy**: Pre-approved, compliant messaging repository for rapid deployment
- **Event Materials**: Professional collateral for conferences, trade shows, and hospital presentations

**Success Metrics:**
- Website traffic increase of 150% by Q2 2025
- 3-5 social posts per week with >5% engagement rate
- Complete video template library (10+ templates) by March 2025
- Brand consistency score of 95%+ across all materials

---

### 2. Operational Excellence & AI Automation

**Primary Goal:** Eliminate manual processes and scale operations to support 10x growth

#### Critical Workflows to Automate
1. **Order Processing**: Replace 4-document manual process with AI-driven automation
   - Reduce order processing time from 15 minutes to <2 minutes
   - Eliminate human error (recent invoice to wrong customer incident)
   - Automated quality check before shipping

2. **CRM Migration & Optimization**: Transition from Monday.com to HubSpot
   - Implement proper sales pipeline tracking with deal stages
   - Enable forecasting and reporting for board meetings
   - Track external sales reps performance and activities

3. **VAC Submissions**: Streamline Value Analysis Committee applications
   - Build repository of pre-approved responses
   - AI-assisted form completion with human review
   - Track submission status and follow-ups

4. **Dealer Management**: Automated monthly summaries and performance tracking

5. **Invoice Generation**: Automated invoice creation from orders to prevent billing errors

**Success Metrics:**
- 80% reduction in order processing time by Q1 2025
- Zero invoicing errors in Q1 2025
- Complete CRM migration by January 2025
- Sales forecast accuracy >85% by Q2 2025
- VAC submission time reduced by 60%

---

### 3. Revenue Growth & Market Expansion

**Primary Goal:** Achieve predictable, scalable revenue growth through systematic sales execution

#### Commercial Expansion
- **US Market**: Expand from 35 to 75 hospitals by Q4 2025
- **International Launch**: Secure regulatory approvals and establish distribution in UK, Middle East, Singapore (Q2-Q3 2025)
- **Sales Rep Network**: Improve tracking, training, and enablement of external sales representatives
- **EVD Launch Preparation**: Build go-to-market strategy for 2026 EVD product launch

#### Sales Enablement
- **Lead Generation**: Implement AI-powered outreach to neurosurgeons and hospital decision-makers
- **KOL Video Library**: Capture testimonials from key opinion leaders (Primary Children's Utah, Cincinnati Children's, Boston Children's)
- **Peer-to-Peer Program**: Develop surgeon-to-surgeon education program
- **Data-Driven Selling**: Leverage multi-center study data showing >50% reduction in revisions

**Success Metrics:**
- 120% of 2024 revenue target
- 40 new hospital accounts by EOY 2025
- 3 international markets operational by Q3 2025
- 15+ KOL video testimonials by Q2 2025
- Sales rep productivity increase of 50%

---

### 4. Fundraising & Investor Relations

**Primary Goal:** Successfully close $2-4M raise and position for Series A in 2026

#### Immediate Actions
- **Round Closure**: Complete current $2-4M raise (targeting Q4 2024 / Q1 2025 close)
- **Investor Deck**: Professional refresh with consistent branding and compelling narrative
- **Investor Outreach**: AI-powered personalized outreach to qualified medical device investors
- **Data Room**: Organize clinical data, financial projections, and supporting materials

#### Ongoing Activities
- **Board Communications**: Monthly updates with clear KPIs and milestones
- **Investor Newsletter**: Quarterly updates via MailChimp to current and prospective investors
- **PR & Media**: Strategic press releases for product milestones, clinical data, and market expansion
- **Series A Preparation**: Build relationships and narrative for 2026 Series A ($15-20M target)

**Success Metrics:**
- Close $2-4M round by Q1 2025
- 50+ qualified investor meetings by Q2 2025
- Media placements in 3+ tier-1 medical device publications
- Series A lead investor identified by Q4 2025

---

### 5. Clinical Excellence & Evidence Generation

**Primary Goal:** Build compelling clinical evidence to support expanded claims and market adoption

#### Data Generation
- **Multi-Center Study**: Complete 3-center, 50-patient study showing significant revision reduction
- **Real-World Evidence**: Systematic collection of usage data and outcomes from commercial sites
- **Publication Strategy**: Target peer-reviewed publications in neurosurgery and hydrocephalus journals
- **Registry Development**: Long-term patient registry for ongoing outcomes tracking

#### Regulatory & Claims
- **FDA Claim Expansion**: Submit data for additional claims around revision reduction
- **OUS Approvals**: CE Mark and other international regulatory clearances for ReFlow™ Mini
- **EVD Breakthrough**: Advance ReFlow™ EVD through Breakthrough Device pathway
- **Monitoring Device**: Progress monitoring system through development and regulatory pathway

**Success Metrics:**
- Multi-center study completed and submitted for publication by Q2 2025
- 2 peer-reviewed publications by EOY 2025
- FDA claim expansion submission by Q3 2025
- CE Mark approval by Q2 2025

---

### 6. Team Development & Organizational Scaling

**Primary Goal:** Build high-performing team capable of supporting rapid growth

#### Hiring Priorities
1. **Marketing Coordinator** (Q1 2025): Support Angela and Sophia with tactical execution, VAC submissions, event coordination
2. **Additional Sales Reps**: Expand coverage in key territories
3. **Customer Success**: Ensure adoption and satisfaction at commercial sites
4. **Operations Support**: Scale order fulfillment and customer service

#### Team Enablement
- **Training Programs**: Comprehensive product, clinical, and sales training for all customer-facing roles
- **AI Tools Adoption**: Train team on custom GPTs, automation tools, and productivity enhancements
- **Process Documentation**: Standard operating procedures for all critical workflows
- **Performance Management**: Clear KPIs and accountability systems

**Success Metrics:**
- Marketing coordinator hired by Q1 2025
- 2 additional sales reps by Q2 2025
- 90%+ employee satisfaction score
- Zero critical process documentation gaps by Q2 2025

---

## Key Performance Indicators (KPIs) - 2025

### Financial
- Revenue: [Target to be confirmed based on forecast]
- Gross Margin: >80%
- Cash Runway: >18 months post-raise close
- Operating Burn: Optimized for path to profitability in 2026

### Commercial
- Commercial Hospitals: 75 (up from 35)
- Units Sold: [Target based on hospital adoption rates]
- Average Order Value: [Baseline + growth target]
- Sales Cycle: Reduce from current baseline by 20%

### Product & Clinical
- EVD Launch: On-time Q1 2026 commercial availability
- Clinical Publications: 2 peer-reviewed articles
- Patient Registry: 150+ enrolled patients
- Product Quality: <1% complaint rate, zero serious adverse events

### Marketing & Brand
- Website Traffic: 150% increase YoY
- Social Media Engagement: 5%+ engagement rate, 10K+ followers across platforms
- Video Content: 50+ pieces of content created
- Lead Generation: 500+ qualified leads generated

### Operational
- Order Processing Time: <2 minutes average
- Invoice Accuracy: 99.5%+
- CRM Data Quality: 95%+ complete and accurate
- Process Automation: 80% of identified manual processes automated

---

## Timeline & Milestones

### Q4 2024 (Oct-Dec)
- ✅ Sixty Seconds engagement signed ($7.5K/mo for 6 months)
- PEDS Conference (Dec 5): Professional booth presence with new video
- Brand refresh initiated
- Website redesign kickoff
- CRM migration planning
- Order automation proof-of-concept
- Current fundraise close target

### Q1 2025 (Jan-Mar)
- Website launch
- Complete brand guidelines
- Social media template library launched
- CRM migration to HubSpot complete
- Order automation live
- Marketing coordinator hired
- Video content library (10+ templates)
- Fundraise officially closed

### Q2 2025 (Apr-Jun)
- Multi-center study publication submitted
- CE Mark approval
- International distribution agreements signed
- KOL video series complete (15+ videos)
- Lead generation campaigns launched
- First international sales
- 50+ new hospital accounts in pipeline

### Q3 2025 (Jul-Sep)
- FDA claim expansion submission
- OUS markets operational (UK, Middle East, Singapore)
- Additional sales reps hired and ramped
- Dealer network expansion
- Marketing coordinator fully productive
- Series A preparation initiated

### Q4 2025 (Oct-Dec)
- 75 commercial hospitals milestone
- EVD launch preparation
- Series A materials complete
- Annual strategic planning for 2026
- Team expansion planning
- Monitoring device regulatory submission preparation

---

## Risk Mitigation

### Key Risks & Mitigation Strategies

1. **Fundraise Delays**
   - Risk: Current raise extends into Q2 2025
   - Mitigation: Maintain 12-month runway, prioritize high-ROI initiatives, have bridge financing options ready

2. **Hospital Adoption Slower Than Forecast**
   - Risk: VAC approval process or clinical adoption barriers
   - Mitigation: Improve VAC submission efficiency, strengthen clinical evidence, expand KOL network

3. **Competitive Response**
   - Risk: Established players develop competing solutions
   - Mitigation: Accelerate patent portfolio, deepen clinical relationships, expand product pipeline

4. **Regulatory Delays**
   - Risk: EVD or monitoring device approval timelines extend
   - Mitigation: Maintain close FDA communication, have regulatory consultants engaged, parallel track international approvals

5. **Operational Scaling Challenges**
   - Risk: Manual processes break under growth pressure
   - Mitigation: Prioritize automation initiatives, hire ahead of growth curve, implement robust QMS

6. **Team Capacity**
   - Risk: Small team overwhelmed with multiple priorities
   - Mitigation: Focus on automation and delegation, hire marketing coordinator immediately, define clear priorities

---

## Success Factors

### What Will Make Us Win

1. **Clinical Evidence**: Compelling data showing >50% reduction in revision surgeries
2. **Ease of Use**: Patient-controlled, non-invasive solution that empowers families
3. **Economic Value**: Reduces costly revision surgeries, covered by insurance
4. **KOL Support**: Leading pediatric neurosurgeons and institutions as advocates
5. **Operational Excellence**: Seamless ordering, delivery, and support experience
6. **Brand Presence**: Professional, consistent, trustworthy brand across all touchpoints
7. **First-Mover Advantage**: Only noninvasive solution for shunt occlusion management
8. **Pipeline Strength**: EVD and monitoring products create platform company narrative

### Critical Dependencies

- Close current fundraise to fuel growth initiatives
- Execute brand and website refresh to support market expansion
- Implement operational automation to scale efficiently
- Secure international regulatory approvals on timeline
- Maintain product quality and patient safety (zero compromises)
- Attract and retain top talent in competitive market
- Build and maintain strong relationships with KOLs and institutions

---

## Notes for Sixty Seconds Partnership

### Immediate Priorities (Nov-Dec 2024)
1. PEDS booth video (deadline: December 4-5)
2. Brand refresh guidelines
3. Website redesign and build
4. Social media content templates
5. Video template library for sales team

### Ongoing Collaboration
- Monthly retainer: $7.5K months 1-6, $5K months 7-12
- Weekly sync calls for project coordination
- Slack channel for rapid communication
- Access to Dropbox for assets and deliverables
- Compliance review process for all materials (Natalie Eagleberger - regulatory lead)

### Key Contacts
- **Elsa Chi Abruzzo** (CEO): Strategic direction, investor relations, regulatory
- **Angela Hale** (VP Commercial): Sales, marketing, VAC submissions, dealer management
- **Sophia Laura DeAraujo** (Commercial Operations): Marketing execution, events, content creation
- **Daryl** (CFO): Budget approvals, financial planning
- **Natalie Eagleberger** (VP Regulatory): Compliance review and approval
- **Stefan**: Marketing consultant recently engaged for additional oversight

---

*Last Updated: November 18, 2024*
*Next Review: January 15, 2025*
